Date: 2011-01-04
Type of information: R&D agreement
Compound: drug targets
Company: Kinaxo Biotechnology (Germany) AstraZeneca (UK)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: Kinaxo Biotechnology has entered into a collaboration with AstraZeneca. The german company will apply its technology platform to support one of AstraZeneca’s oncology programs. Its high-end mass spectrometry-based technologies will be used to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. These analysis aim to gain valuable insights into cellular functions of potential drug targets .
Financial terms: Financial details of the agreement were not disclosed.
Latest news: